Although China accounts for nearly twenty percent of the world’s population, it represents only around two percent of the global drug market. However, it is growing rapidly as China’s changing health care environment is designed to extend basic health care to a larger portion of the population and give individuals greater access to products and services. Because the domestic pharmaceutical industry in China is highly fragmented, there is a large demand for proven pharmaceutical products from other parts of the world, particularly the United States and Europe.
Chinese consumers are well aware of the critical manufacturing requirements of pharmaceutical products. They have already experienced less than optimum results from products that have not been manufactured using the stringent requirements that products made in the United States or other parts of the world have. Suzhou Pharma Services offers pharmaceutical companies local manufacturing in this large, rapidly growing market.
Suzhou Pharma Services brings manufacturing capability that uses proven equipment, technology, and manufacturing systems that are FDA approved and utilize cGMP practices to assure high quality. We understand the issues that have come from products being manufactured in China in the past, but our Western-style leadership allows us to deliver quality that will greatly benefit both the customer and the ultimate consumer.
Suzhou Pharma Services also offers pharmaceutical companies an alternative to the use of their own capital expenditures to invest in new facilities in China. Not only is capital preserved, speed to market is greatly enhanced. Suzhou Pharma Services can also provide complementary support for products that are rapidly growing and outstripping a company’s own manufacturing capacity.